Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

The success of therapies for metastatic CRPC continues.

Shore ND.

Oncology (Williston Park). 2013 Nov;27(11):1160-1. No abstract available.

2.

Sequencing medical therapy in prostate cancer: not as easy as 1-2-3.

Kessler ER, Flaig TW.

Oncology (Williston Park). 2013 Nov;27(11):1158-60. No abstract available.

3.

Prostate cancer: Dasatinib fails to improve on docetaxel for metastatic CRPC.

Phillips R.

Nat Rev Urol. 2014 Jan;11(1):5. doi: 10.1038/nrurol.2013.283. No abstract available.

PMID:
24296705
4.

Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: retrospective analysis of a single institution experience.

Grenader T, Plotkin Y, Gips M, Cherny N, Gabizon A.

Oncol Rep. 2014 Jan;31(1):428-34. doi: 10.3892/or.2013.2852.

PMID:
24247716
5.

A urologic oncology roundtable discussion: issues to consider in choosing treatment for metastatic castration-resistant prostate cancer.

Taplin ME, Berry WR, Casey AM, Aslo A.

Hosp Pract (1995). 2013 Oct-Nov;41(4):81-2. doi: 10.3810/hp.2013.10.1084.

PMID:
24145593
6.

Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.

Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.

J Urol. 2014 Jan;191(1):227-34. doi: 10.1016/j.juro.2013.07.101.

PMID:
23954373
7.

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.

Dellis A, Papatsoris AG.

Expert Opin Biol Ther. 2014 Jan;14(1):7-10. doi: 10.1517/14712598.2013.840582.

PMID:
24074253
8.

Should we give metformin to all men with CRPC?

Clyne M.

Nat Rev Urol. 2014 Feb;11(2):63. doi: 10.1038/nrurol.2014.7. No abstract available.

PMID:
24445914
9.

Current, new and novel therapy for castration-resistant prostate cancer.

Gaya JM, Ahallal Y, Sanchez-Salas R, Barret E, Rozet F, Galiano M, Macek P, Durand M, Cerruti J, Prapotnich D, Ropert S, Bennamoun M, Cathelineau X.

Expert Rev Anticancer Ther. 2013 Jul;13(7):819-27. doi: 10.1586/14737140.2013.811154. Review.

PMID:
23875660
10.

A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.

Shore ND, Concepcion R, Barocas DA.

Hosp Pract (1995). 2013 Oct-Nov;41(4):78-80. doi: 10.3810/hp.2013.10.1083.

PMID:
24145592
11.

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.

Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788.

PMID:
24668612
12.

A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer.

Ryan C, Shore ND, Concepcion R.

Postgrad Med. 2013 Nov;125(6):114-6. doi: 10.3810/pgm.2013.11.2718.

PMID:
24200767
13.

[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].

Basset V, Flamand V, Crouzet S, Ploussard G.

Prog Urol. 2013 Oct;23 Suppl 1:S44-8. doi: 10.1016/S1166-7087(13)70045-9. Review. French.

PMID:
24314738
14.

[Recent advances in treatment of patients with castration-resistant prostate cancer after docetaxel failure].

Chen BD, Yu SC, Li GH.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Jan;43(1):115-8. Review. Chinese.

PMID:
24616470
15.

[Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer].

Wang B, Wu KJ, He DL.

Zhonghua Nan Ke Xue. 2013 Aug;19(8):736-41. Review. Chinese.

PMID:
24010211
16.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Cancer. 2013 Aug 15;119(16):2990-8. doi: 10.1002/cncr.28102.

17.

External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer.

Nakano K, Komatsu K, Kubo T, Natsui S, Nukui A, Kurokawa S, Kobayashi M, Morita T.

BMC Urol. 2014 Apr 18;14:31. doi: 10.1186/1471-2490-14-31.

18.

[The efficacy of ethinylestradiol for castration-resistant prostate cancer].

Hayashi T, Sekii Y, Katayama K, Kamoto A, Kakuta Y, Mori N, Itatani H, Yoshioka T.

Nihon Hinyokika Gakkai Zasshi. 2014 Apr;105(2):37-42. Japanese.

PMID:
24908814
19.
20.

Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer.

Batty N, Yarlagadda N, Pili R.

J Natl Compr Canc Netw. 2013 Aug;11(8):911-5.

PMID:
23946170
Items per page

Supplemental Content

Support Center